Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Completed · Phase 1/Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. GM-CSF may stimulate the immune system in different ways and stop tumor cells from growing. Giving lenalidomide together with GM-CSF may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide when given together with GM-CSF and to see how well it works in treating patients with prostate cancer.
Key facts
- Study ID
- NCT00939510
- Run by
- Robert Dreicer MD
- People needed
- 32
- Starts
- 2005-07-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2013-01-31
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.